ALDX vs. PYXS, OMER, TSVT, GTHX, DSGN, FHTX, QURE, PBYI, IMMP, and AKBA
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Pyxis Oncology (PYXS), Omeros (OMER), 2seventy bio (TSVT), G1 Therapeutics (GTHX), Design Therapeutics (DSGN), Foghorn Therapeutics (FHTX), uniQure (QURE), Puma Biotechnology (PBYI), Immutep (IMMP), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
Pyxis Oncology's return on equity of -24.69% beat Aldeyra Therapeutics' return on equity.
Pyxis Oncology has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Pyxis Oncology currently has a consensus target price of $8.80, suggesting a potential upside of 112.05%. Aldeyra Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 136.29%. Given Pyxis Oncology's higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Pyxis Oncology.
Aldeyra Therapeutics received 460 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 69.36% of users gave Aldeyra Therapeutics an outperform vote.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 8.4% of Pyxis Oncology shares are held by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pyxis Oncology had 13 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 14 mentions for Pyxis Oncology and 1 mentions for Aldeyra Therapeutics. Pyxis Oncology's average media sentiment score of 0.85 beat Aldeyra Therapeutics' score of 0.46 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Summary
Aldeyra Therapeutics beats Pyxis Oncology on 9 of the 13 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
